Biomarin Pharmaceutical (BMRN) EBIT Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) EBIT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
100.00% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
12.69% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
75.16% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
1.27% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-347.04% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.00% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
80.62% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
-42.10% |
| Date | Value |
|---|
| Mar 31, 2026 |
-42.10% |
| Dec 31, 2025 |
-127.64% |
| Sep 30, 2025 |
-141.00% |
| Jun 30, 2025 |
129.87% |
| Mar 31, 2025 |
153.10% |
| Dec 31, 2024 |
491.69% |
| Sep 30, 2024 |
273.11% |
| Jun 30, 2024 |
83.71% |
| Mar 31, 2024 |
41.76% |
| Dec 31, 2023 |
308.43% |
| Sep 30, 2023 |
1,362.93% |
| Jun 30, 2023 |
67.47% |
| Mar 31, 2023 |
-54.56% |
| Dec 31, 2022 |
80.13% |
| Sep 30, 2022 |
95.46% |
| Jun 30, 2022 |
235.44% |
| Mar 31, 2022 |
447.42% |
| Dec 31, 2021 |
-27.89% |
| Sep 30, 2021 |
4.87% |
| Jun 30, 2021 |
128.51% |
